FDA clears Alebund AP308 IND for first-in-human IgA nephropathy study
The FDA has cleared Alebund Pharmaceuticals’ AP308 IND, allowing a first-in-human study of an engineered IgA protease designed to remove pathogenic IgA and immune complexes in IgA nephropathy.